Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

Nivolumab-refractory patients with advanced non-small-cell lung cancer.

Costantini A, Fallet V, Corny J, Friard S, Chouaid C, Duchemann B, Giroux-Leprieur E, Taillade L, Doucet L, Brosseau S, Wislez M, Tredaniel J, Cadranel J.

Lung Cancer. 2019 Apr;130:128-134. doi: 10.1016/j.lungcan.2019.01.015. Epub 2019 Feb 14.

PMID:
30885333
2.

I-O Optimise: a novel multinational real-world research platform in thoracic malignancies.

Ekman S, Griesinger F, Baas P, Chao D, Chouaid C, O'Donnell JC, Penrod JR, Daumont M, Lacoin L, McKenney A, Khovratovich M, Munro RE, Durand-Zaleski I, Johnsen SP.

Future Oncol. 2019 Mar 11. doi: 10.2217/fon-2019-0025. [Epub ahead of print]

3.

First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.

Bylicki O, Barazzutti H, Paleiron N, Margery J, Assié JB, Chouaïd C.

BioDrugs. 2019 Mar 2. doi: 10.1007/s40259-019-00339-4. [Epub ahead of print] Review.

PMID:
30825132
4.

The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims Database.

Bourdin A, Fabry-Vendrand C, Ostinelli J, Ait-Yahia M, Darnal E, Bouee S, Laurendeau C, Bureau I, Gourmelen J, Chouaid C.

J Allergy Clin Immunol Pract. 2019 Jan 25. pii: S2213-2198(19)30079-0. doi: 10.1016/j.jaip.2018.12.029. [Epub ahead of print]

PMID:
30685573
5.

Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France.

Chouaid C, Germain N, De Pouvourville G, Aballéa S, Korchagina D, Baldwin M, Le Lay K, Luciani L, Toumi M, Devillier P.

Curr Med Res Opin. 2019 Feb 15:1-8. doi: 10.1080/03007995.2019.1574507. [Epub ahead of print]

PMID:
30681007
6.

Continuity of care in general practice at cancer diagnosis (COOC-GP study): a national cohort study of 2853 patients.

Hurtaud A, Aubin M, Ferrat E, Lebreton J, Paillaud E, Audureau E, Bastuji-Garin S, Chouaid C, Boisnault P, Clerc P, Canouï-Poitrine F.

Br J Gen Pract. 2019 Feb;69(679):e88-e96. doi: 10.3399/bjgp19X700805. Epub 2019 Jan 14.

PMID:
30642910
7.

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.

Auliac JB, Pérol M, Planchard D, Monnet I, Wislez M, Doubre H, Guisier F, Pichon E, Greillier L, Mastroianni B, Decroisette C, Schott R, Le Moulec S, Arrondeau J, Cortot AB, Gerinière L, Renault A, Daniel C, Falchero L, Chouaid C.

Lung Cancer. 2019 Jan;127:96-102. doi: 10.1016/j.lungcan.2018.11.037. Epub 2018 Nov 27.

PMID:
30642559
8.

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.

Chouaid C, Bensimon L, Clay E, Millier A, Levy-Bachelot L, Huang M, Levy P.

Lung Cancer. 2019 Jan;127:44-52. doi: 10.1016/j.lungcan.2018.11.008. Epub 2018 Nov 23.

9.

Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-small-cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB).

Chouaid C, Salaün M, Gounant V, Febvre M, Vergnon JM, Jouniaux V, Fournier C, Lachkar S, Hermant C, Raspaud C, Quantin X, Quiot JJ, Molard A, Dayen C, Marquette CH, Lena H, Zalcman G, Thiberville L.

PLoS One. 2019 Jan 7;14(1):e0208992. doi: 10.1371/journal.pone.0208992. eCollection 2019.

10.

Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14.

Auliac JB, Bayle S, Vergnenegre A, Le Caer H, Falchero L, Gervais R, Doubre H, Vinas F, Marin B, Chouaid C.

Curr Oncol. 2018 Oct;25(5):e398-e402. doi: 10.3747/co.25.3945. Epub 2018 Oct 31.

11.

Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study.

Scherpereel A, Durand-Zaleski I, Cotté FE, Fernandes J, Debieuvre D, Blein C, Gaudin AF, Tournier C, Vainchtock A, Chauvin P, Souquet PJ, Westeel V, Chouaïd C.

BMC Cancer. 2018 Oct 22;18(1):1013. doi: 10.1186/s12885-018-4958-5.

12.

Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC.

Lesueur P, Escande A, Thariat J, Vauléon E, Monnet I, Cortot A, Lerouge D, Danhier S, Dô P, Dubos-Arvis C, Chouaïd C, Gervais R.

Cancer Med. 2018 Nov;7(11):5505-5513. doi: 10.1002/cam4.1825. Epub 2018 Oct 11.

13.

Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France.

Bigay-Gamé L, Bota S, Greillier L, Monnet I, Madroszyk A, Corre R, Mastroianni B, Falchero L, Mazières J, Colineaux H, Lepage B, Chouaid C; GFPC Investigators.

Oncology. 2018;95(6):337-343. doi: 10.1159/000489784. Epub 2018 Oct 2.

PMID:
30278447
14.

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial.

Meyer G, Besse B, Doubre H, Charles-Nelson A, Aquilanti S, Izadifar A, Azarian R, Monnet I, Lamour C, Descourt R, Oliviero G, Taillade L, Chouaid C, Giraud F, Falcoz PE, Revel MP, Westeel V, Dixmier A, Tredaniel J, Dehette S, Decroisette C, Prevost A, Pichon E, Fabre E, Soria JC, Friard S, Stern JB, Jabot L, Dennewald G, Pavy G, Petitpretz P, Tourani JM, Alifano M, Chatellier G, Girard P.

Eur Respir J. 2018 Oct 4;52(4). pii: 1801220. doi: 10.1183/13993003.01220-2018. Print 2018 Oct.

PMID:
30262574
15.

Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review.

Lesueur P, Martel-Laffay I, Escande A, Kissel M, Locher C, Gervais R, Schott R, Vergnenegre A, Chouaid C.

Expert Rev Anticancer Ther. 2018 Nov;18(11):1159-1165. doi: 10.1080/14737140.2018.1518714. Epub 2018 Sep 17.

PMID:
30173589
16.

Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.

Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Price M, Chirila C, Hollis K, Sweeney C, Wolowacz S, Kaye JA, Kontoudis I.

Lung Cancer. 2018 Oct;124:310-316. doi: 10.1016/j.lungcan.2018.07.042. Epub 2018 Aug 10.

17.

Lung cancer and interstitial lung disease: a literature review.

Naccache JM, Gibiot Q, Monnet I, Antoine M, Wislez M, Chouaid C, Cadranel J.

J Thorac Dis. 2018 Jun;10(6):3829-3844. doi: 10.21037/jtd.2018.05.75. Review.

18.

Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.

Saboundji K, Auliac JB, Pérol M, François G, Janicot H, Marcq M, Dubos-Arvis C, Renault A, Guisier F, Odier L, Gervais R, Chouaïd C.

Target Oncol. 2018 Aug;13(4):501-507. doi: 10.1007/s11523-018-0581-2.

PMID:
30039345
19.

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab.

Bylicki O, Paleiron N, Rousseau-Bussac G, Chouaïd C.

Onco Targets Ther. 2018 Jul 16;11:4051-4064. doi: 10.2147/OTT.S154606. eCollection 2018. Review.

20.

Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review.

Babey H, Quéré G, Descourt R, Le Calloch R, Lanfranco L, Nousbaum JB, Cornec D, Tison A, Chouaid C.

Expert Rev Anticancer Ther. 2018 Oct;18(10):981-989. doi: 10.1080/14737140.2018.1499468. Epub 2018 Jul 20. Review.

PMID:
29995451
21.

Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).

Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C, Hollis K, Sweeney C, Price M, Wolowacz S, Kaye JA, Kontoudis I.

Lung Cancer. 2018 Oct;124:298-309. doi: 10.1016/j.lungcan.2018.06.007. Epub 2018 Jun 9.

22.

Are Systemic Manifestations Ascribable to COPD in Smokers? A Structural Equation Modeling Approach.

Boyer L, Bastuji-Garin S, Chouaid C, Housset B, Le Corvoisier P, Derumeaux G, Boczkowski J, Maitre B, Adnot S, Audureau E.

Sci Rep. 2018 Jun 5;8(1):8569. doi: 10.1038/s41598-018-26766-x.

23.

Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC).

Vergnenègre A, Chouaïd C.

Expert Rev Pharmacoecon Outcomes Res. 2018 Oct;18(5):519-528. doi: 10.1080/14737167.2018.1485099. Epub 2018 Jun 14. Review.

PMID:
29869900
24.

Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06).

Locher C, Pourel N, Le Caer H, Berard H, Auliac JB, Monnet I, Descourt R, Vergnenègre A, Lafay IM, Greillier L, Chouaïd C.

Lung Cancer. 2018 Jul;121:25-29. doi: 10.1016/j.lungcan.2018.04.017. Epub 2018 Apr 22.

PMID:
29858022
25.

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer.

Costantini A, Corny J, Fallet V, Renet S, Friard S, Chouaid C, Duchemann B, Giroux-Leprieur E, Taillade L, Doucet L, Nguenang M, Jouveshomme S, Wislez M, Tredaniel J, Cadranel J.

ERJ Open Res. 2018 Apr 20;4(2). pii: 00120-2017. doi: 10.1183/23120541.00120-2017. eCollection 2018 Apr.

26.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators.

Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.

PMID:
29545095
27.

Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study).

Corre R, Gervais R, Guisier F, Tassy L, Vinas F, Lamy R, Fraboulet G, Greillier L, Doubre H, Descourt R, Chouaid C, Auliac JB.

Oncotarget. 2018 Jan 2;9(9):8253-8262. doi: 10.18632/oncotarget.23836. eCollection 2018 Feb 2.

28.

Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis.

Chouaid C, Assié JB, Andujar P, Blein C, Tournier C, Vainchtock A, Scherpereel A, Monnet I, Pairon JC.

Cancer Med. 2018 Apr;7(4):1102-1109. doi: 10.1002/cam4.1378. Epub 2018 Feb 26.

29.

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.

Cadranel J, Cortot AB, Lena H, Mennecier B, Do P, Dansin E, Mazieres J, Chouaid C, Perol M, Barlesi F, Robinet G, Friard S, Thiberville L, Audigier-Valette C, Vergnenegre A, Westeel V, Slimane K, Buturuga A, Moro-Sibilot D, Besse B.

ERJ Open Res. 2018 Feb 13;4(1). pii: 00058-2017. doi: 10.1183/23120541.00058-2017. eCollection 2018 Jan.

30.

Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.

Gauvain C, Vauléon E, Chouaid C, Le Rhun E, Jabot L, Scherpereel A, Vinas F, Cortot AB, Monnet I.

Lung Cancer. 2018 Feb;116:62-66. doi: 10.1016/j.lungcan.2017.12.008. Epub 2017 Dec 14.

PMID:
29413052
31.

Beclin1 circulating levels and accelerated aging markers in COPD.

Schlemmer F, Boyer L, Soumagne T, Ridoux A, Chouaid C, Maitre B, Lanone S, Adnot S, Audureau E, Boczkowski J.

Cell Death Dis. 2018 Feb 5;9(2):156. doi: 10.1038/s41419-017-0178-1. No abstract available.

32.

Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment.

Picchi H, Mateus C, Chouaid C, Besse B, Marabelle A, Michot JM, Champiat S, Voisin AL, Lambotte O.

Clin Microbiol Infect. 2018 Mar;24(3):216-218. doi: 10.1016/j.cmi.2017.12.003. Epub 2017 Dec 18. No abstract available.

33.

Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group.

Le Caer H, Borget I, Corre R, Locher C, Raynaud C, Decroisette C, Berard H, Audigier-Valette C, Dujon C, Auliac JB, Crequit J, Monnet I, Vergnenegre A, Chouaid C.

J Thorac Dis. 2017 Oct;9(10):3747-3754. doi: 10.21037/jtd.2017.09.51.

34.

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim SW, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim DW, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB.

J Thorac Oncol. 2018 Apr;13(4):576-584. doi: 10.1016/j.jtho.2017.11.131. Epub 2017 Dec 13.

PMID:
29247830
35.

Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France.

Pignata M, Chouaid C, Le Lay K, Luciani L, McConnachie C, Gordon J, Roze S.

Clinicoecon Outcomes Res. 2017 Oct 25;9:655-668. doi: 10.2147/CEOR.S136657. eCollection 2017.

36.

PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION.

Tordrup D, Chouaid C, Cuijpers P, Dab W, van Dongen JM, Espin J, Jönsson B, Léonard C, McDaid D, McKee M, Miguel JP, Patel A, Reginster JY, Ricciardi W, Rutten-van Molken M, Rupel VP, Sach T, Sassi F, Waugh N, Bertollini R.

Int J Technol Assess Health Care. 2017 Jan;33(6):609-619. doi: 10.1017/S0266462317000666. Epub 2017 Oct 30.

38.

Association between lung cancer somatic mutations and occupational exposure in never-smokers.

Paris C, Do P, Mastroianni B, Dixmier A, Dumont P, Pichon E, Chouaid C, Coudert B, Foucher P, Fraboulet S, Locatelli-Sanchez M, Baize N, Dansin E, Moreau L, Vincent M, Missy P, Morin F, Moro-Sibilot D, Couraud S; BioCAST/IFCT-1002 study investigators; to the BioCAST/IFCT- 1002 study.

Eur Respir J. 2017 Oct 26;50(4). pii: 1700716. doi: 10.1183/13993003.00716-2017. Print 2017 Oct.

PMID:
29074543
39.

Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE).

Bennouna J, Falchero L, Schott R, Bonnetain F, Coudert M, Ben Hadj Yahia B, Chouaid C.

Oncology. 2018;94(1):55-64. doi: 10.1159/000480702. Epub 2017 Oct 25.

PMID:
29065416
40.

Impaired humoral and cellular immune responses to influenza vaccination in chronic obstructive pulmonary disease patients.

Parpaleix A, Boyer L, Wiedemann A, Lacabaratz C, Margarit L, Enouf V, Le Corvoisier P, Lino A, Covali-Noroc A, Housset B, Chouaid C, Maitre B, Lévy Y, Lelièvre JD, Adnot S.

J Allergy Clin Immunol. 2017 Dec;140(6):1754-1757.e6. doi: 10.1016/j.jaci.2017.07.038. Epub 2017 Sep 7. No abstract available.

PMID:
28889955
41.

A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France.

Taipale K, Winfree KB, Boye M, Basson M, Sleilaty G, Eaton J, Evans R, Chouaid C.

Clinicoecon Outcomes Res. 2017 Aug 16;9:505-518. doi: 10.2147/CEOR.S128371. eCollection 2017.

42.

Second-line treatments of small-cell lung cancers.

Baize N, Monnet I, Greillier L, Quere G, Kerjouan M, Janicot H, Vergnenegre A, Auliac JB, Chouaid C.

Expert Rev Anticancer Ther. 2017 Nov;17(11):1033-1043. doi: 10.1080/14737140.2017.1372198. Epub 2017 Sep 8. Review.

PMID:
28849951
43.

Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study).

Chouaïd C, Debieuvre D, Durand-Zaleski I, Fernandes J, Scherpereel A, Westeel V, Blein C, Gaudin AF, Ozan N, Leblanc S, Vainchtock A, Chauvin P, Cotté FE, Souquet PJ.

PLoS One. 2017 Aug 25;12(8):e0182798. doi: 10.1371/journal.pone.0182798. eCollection 2017.

44.

Analysis of health economics assessment reports for pharmaceuticals in France - understanding the underlying philosophy of CEESP assessment.

Toumi M, Motrunich A, Millier A, Rémuzat C, Chouaid C, Falissard B, Aballéa S.

J Mark Access Health Policy. 2017 Jul 16;5(1):1344088. doi: 10.1080/20016689.2017.1344088. eCollection 2017.

45.

Cost analysis of adverse events associated with non-small cell lung cancer management in France.

Chouaid C, Loirat D, Clay E, Millier A, Godard C, Fannan A, Lévy-Bachelot L, Angevin E.

Clinicoecon Outcomes Res. 2017 Jul 27;9:443-449. doi: 10.2147/CEOR.S138963. eCollection 2017.

46.

Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).

Auliac JB, Monnet I, Dubos-Arvis C, Chiappa AM, Baize N, Bota S, Vergnenegre A, Doubre H, Locher C, Bizieux A, Robinet G, Chouaid C.

Target Oncol. 2017 Dec;12(6):833-838. doi: 10.1007/s11523-017-0520-7.

PMID:
28762087
47.

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers.

Chouaid C, Luciani L, LeLay K, Do P, Bennouna J, Perol M, Moro-Sibilot D, Vergnenègre A, de Pouvourville G.

J Thorac Oncol. 2017 Oct;12(10):1496-1502. doi: 10.1016/j.jtho.2017.07.013. Epub 2017 Jul 24.

48.

Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.

Bylicki O, Paleiron N, Margery J, Guisier F, Vergnenegre A, Robinet G, Auliac JB, Gervais R, Chouaid C.

Target Oncol. 2017 Oct;12(5):563-569. doi: 10.1007/s11523-017-0510-9. Review.

PMID:
28624922
49.

[Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].

Caliez J, Monnet I, Pujals A, Rousseau-Bussac G, Jabot L, Boudjemaa A, Leroy K, Chouaid C.

Rev Mal Respir. 2017 May;34(5):576-580. doi: 10.1016/j.rmr.2016.08.002. Epub 2016 Sep 17. French.

PMID:
27646667
50.

Reply to R.D. Nipp et al, M.-J. Molina-Garrido et al, and A. Gajra et al.

Corre R, Léna H, Vergnenègre A, Chouaïd C.

J Clin Oncol. 2016 Nov 20;34(33):4050-4051. doi: 10.1200/JCO.2016.69.1105. Epub 2016 Oct 31. No abstract available.

PMID:
27551125

Supplemental Content

Loading ...
Support Center